Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, Moore M, Chan SL, Mant A, Eek R, Zielinski R, Su R, Pan Z, Ma Y, Li F, Li P, Tse AN. Bishnoi S, et al. Among authors: li f, li p. Cancer. 2024 Jun 1;130(11):1991-2002. doi: 10.1002/cncr.35226. Epub 2024 Feb 26. Cancer. 2024. PMID: 38404184 Clinical Trial.
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
Day D, Park JJ, Coward J, Markman B, Lemech C, Kuo JC, Prawira A, Brown MP, Bishnoi S, Kotasek D, Strother RM, Cosman R, Su R, Ma Y, Yue Z, Hu HH, Wu R, Li P, Tse AN. Day D, et al. Among authors: li p. Br J Cancer. 2023 Nov;129(10):1608-1618. doi: 10.1038/s41416-023-02431-7. Epub 2023 Sep 20. Br J Cancer. 2023. PMID: 37731023 Free PMC article. Clinical Trial.
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Gong J, Guo Y, Zhang Y, Ba Y, Chen T, Li W, Zhou C, Wang M, Yang H, Zhou Y, Cai Q, Wang Z, Huang G, Zhang W, Su R, Cai Z, Yue Z, Dou J, Li P, Wu R, Tse AN, Shen L. Gong J, et al. Among authors: li w, li p. Target Oncol. 2024 Sep;19(5):723-733. doi: 10.1007/s11523-024-01091-8. Epub 2024 Sep 4. Target Oncol. 2024. PMID: 39231855 Clinical Trial.
Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.
Wang H, Cui G, Cheng M, Aji T, Li G, Hu X, Li G, Zhang S, Zhang Y, Diao L, Li P, Wang L, Yuan Y, Qian G, Zhang R, Jin X, Wang J, Luo H, Zhang D, Wang M, Li S, Song Z, Yang M, Su G, Sun R, Chang J, Yu Z, Ren Z. Wang H, et al. Among authors: li p. Signal Transduct Target Ther. 2025 Jan 17;10(1):30. doi: 10.1038/s41392-025-02126-w. Signal Transduct Target Ther. 2025. PMID: 39819859
36,589 results
You have reached the last available page of results. Please see the User Guide for more information.